Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares gained 1.22%, or $0.73 per share, to close Friday at $60.52. After opening the day at $59.82, shares of Arrowhead fluctuated between $61.80 and $58.95. 554,758 shares traded hands a decrease from their 30 day average of 693,446. Friday’s activity brought Arrowhead’s market cap to $6,309,770,173.
Arrowhead is headquartered in Pasadena, California..
About Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.